Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment von Qi, Zhi, Xu, Zihan, Zhang, Liuzhen, Zou, Yongkang, Li, Jinping, Yan, Wenyu, Li, Cheng, Liu, Ningshu, Wu, Hong

Volltext

T-ALL leukemia stem cell 'stemness' is epigenetically controlled by the master regulator SPI1 von Zhu, Haichuan, Zhang, Liuzhen, Wu, Yilin, Dong, Bingjie, Guo, Weilong, Wang, Mei, Yang, Lu, Fan, Xiaoying, Tang, Yuliang, Liu, Ningshu, Lei, Xiaoguang, Wu, Hong

Volltext

Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activit... von Wei, Ruicheng, Zhang, Wenli, Yang, Futang, Li, Qianhao, Wang, Qingyu, Liu, Ningshu, Zhu, Jun, Shan, Yongqiang

Volltext

Retraction Note: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT von Hill, Richard, Madureira, Patricia A., Ferreira, Bibiana, Baptista, Inês, Machado, Susana, Colaҫo, Laura, dos Santos, Marta, Liu, Ningshu, Dopazo, Ana, Ugurel, Selma, Adrienn, Angyal, Kiss-Toth, Endre, Isbilen, Murat, Gure, Ali O., Link, Wolfgang

Volltext

Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946) von Scott, William J., Hentemann, Martin F., Rowley, R. Bruce, Bull, Cathy O., Jenkins, Susan, Bullion, Ann M., Johnson, Jeffrey, Redman, Anikó, Robbins, Arthur H., Esler, William, Fracasso, R. Paul, Garrison, Timothy, Hamilton, Mark, Michels, Martin, Wood, Jill E., Wilkie, Dean P., Xiao, Hong, Levy, Joan, Stasik, Enrico, Liu, Ningshu, Schaefer, Martina, Brands, Michael, Lefranc, Julien

Volltext

Acetyl-CoA carboxylase inhibitors attenuate WNT and Hedgehog signaling and suppress pancreatic tumor growth von Petrova, Elissaveta, Scholz, Arne, Paul, Juliane, Sturz, Andrea, Haike, Katja, Siegel, Franziska, Mumberg, Dominik, Liu, Ningshu

Volltext

Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responses von Heller, Simon, Glaeske, Sarah, Gluske, Katja, Paul, Juliane, Böhme, Annika, Janzer, Andreas, Roider, Helge Gottfried, Montebaur, Anna, Nicke, Barbara, Lesche, Ralf, von Ahsen, Oliver, Politz, Oliver, Liu, Ningshu, Gorjánácz, Mátyás

Volltext

RETRACTED ARTICLE: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT von Hill, Richard, Madureira, Patricia A., Ferreira, Bibiana, Baptista, Inês, Machado, Susana, Colaço, Laura, dos Santos, Marta, Liu, Ningshu, Dopazo, Ana, Ugurel, Selma, Adrienn, Angyal, Kiss-Toth, Endre, Isbilen, Murat, Gure, Ali O., Link, Wolfgang

Volltext

Doxorubicin-induced activation of NF-κB in melanoma cells is abrogated by inhibition of IKKβ, but not by a novel IKKα inhibitor von Pletz, Nadin, Schön, Margarete, Ziegelbauer, Karl, Emmert, Steffen, Liu, Ningshu, Dobbelstein, Matthias, Schön, Michael P.

Volltext

Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT von Paul, Juliane, Soujon, Maurice, Wengner, Antje M., Zitzmann-Kolbe, Sabine, Sturz, Andrea, Haike, Katja, Keng Magdalene, Koh Hui, Tan, Sze Huey, Lange, Martin, Tan, Soo Yong, Mumberg, Dominik, Lim, Soon Thye, Ziegelbauer, Karl, Liu, Ningshu

Volltext

BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models von Liu, Ningshu, Rowley, Bruce R, Bull, Cathy O, Schneider, Claudia, Haegebarth, Andrea, Schatz, Christoph A, Fracasso, Paul R, Wilkie, Dean P, Hentemann, Martin, Wilhelm, Scott M, Scott, William J, Mumberg, Dominik, Ziegelbauer, Karl

Volltext

Additional file 2 of Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to pot... von Wei, Ruicheng, Zhang, Wenli, Yang, Futang, Li, Qianhao, Wang, Qingyu, Liu, Ningshu, Zhu, Jun, Shan, Yongqiang

Volltext bestellen

Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling von Will, Marie, Qin, Alice Can Ran, Toy, Weiyi, Yao, Zhan, Rodrik-Outmezguine, Vanessa, Schneider, Claudia, Huang, Xiaodong, Monian, Prashant, Jiang, Xuejun, de Stanchina, Elisa, Baselga, José, Liu, Ningshu, Chandarlapaty, Sarat, Rosen, Neal

Volltext

Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ Inhibitor BAY1082439 von Zou, Yongkang, Qi, Zhi, Guo, Weilong, Zhang, Liuzhen, Ruscetti, Marcus, Shenoy, Tanu, Liu, Ningshu, Wu, Hong

Volltext

A new model of cell cycle-regulated transcription : Repression of the cyclin A promoter by CDF-1 and anti-repression by E2F von NINGSHU LIU, LUCIBELLO, F. C, ENGELAND, K, MÜLLER, R

Volltext

TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT von Hill, Richard, Madureira, Patricia A, Ferreira, Bibiana, Baptista, Inês, Machado, Susana, Colaço, Laura, Dos Santos, Marta, Liu, Ningshu, Dopazo, Ana, Ugurel, Selma, Adrienn, Angyal, Kiss-Toth, Endre, Isbilen, Murat, Gure, Ali O, Link, Wolfgang

Volltext

BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling‐dependent tumor growth in mouse models von Politz, Oliver, Siegel, Franziska, Bärfacker, Lars, Bömer, Ulf, Hägebarth, Andrea, Scott, William J., Michels, Martin, Ince, Stuart, Neuhaus, Roland, Meyer, Kirstin, Fernández‐Montalván, Amaury Ernesto, Liu, Ningshu, von Nussbaum, Franz, Mumberg, Dominik, Ziegelbauer, Karl

Volltext

Co-Targeting the Cell Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ inhibitor BAY1082439 von Zou, Yongkang, Qi, Zhi, Guo, Weilong, Zhang, Liuzhen, Ruscetti, Marcus, Shenoy, Tanu, Liu, Ningshu, Wu, Hong

Volltext

Abstract 1722: Hedgehog and Wnt crosstalk in pancreatic cancer von Petrova, Elissaveta, Scholz, Arne, Paul, Juliane, Sturz, Andrea, Haike, Katja, Siegel, Franziska, Mumberg, Dominik, Liu, Ningshu

Volltext

Efficacy of phosphatidylinositol‐3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells von Göckeritz, Elisa, Kerwien, Susan, Baumann, Michael, Wigger, Marion, Vondey, Verena, Neumann, Lars, Landwehr, Thomas, Wendtner, Clemens M., Klein, Christian, Liu, Ningshu, Hallek, Michael, Frenzel, Lukas P., Krause, Günter

Volltext